Pharmaceuticals

Fudan-Zhangjiang

Fudan-Zhangjiang released FY2026 Q1 earnings on April 30 After-Market (BJT), actual revenue CNY 149.05 M, actual EPS CNY 0.01

Fudan-Zhangjiang FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

Fudan-Zhangjiang to Release FY2025 Earnings Report on March 30 During-Market BJT

Fudan-Zhangjiang released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 134.72 M, actual EPS CNY -0.0805

Fudan-Zhangjiang released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 685.8 M, actual EPS CNY -0.1518

Fudan Zhangjiang Anticipates Net Loss of RMB 120 Million to 180 Million for 2025

Fudan Zhangjiang Receives Acceptance for Clinical Trial Application of FZ-P001 Sodium

Fudan Zhangjiang Changes A-Share Raised Funds Purpose to Support Photodynamic Drug R&D

Fudan-Zhangjiang released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 160.99 M, actual EPS CNY -0.0828

Fudan-Zhangjiang released FY2025 9 Months Earnings on October 30 After-Market (BJT), Actual Revenue: CNY 551.08 M, Actual EPS: CNY -0.0773

Fudan-Zhangjiang to Release FY2025 Q3 Earnings on October 30 After-Market BJT

Affiliate of Fudan Zijang's Obeticholic Acid Tablets Application for Market Approval Rejected

Fudan Zhangjiang Reports 91.89% Drop in Net Profit in H1 2025

Fudan-Zhangjiang released FY2025 Semi-Annual earnings on August 12 After-Market (BJT), actual revenue CNY 390.08 M, actual EPS CNY 0.0055

Fudan-Zhangjiang released FY2025 Q2 earnings on August 12 After-Market BJT, actual revenue CNY 210.18 M, actual EPS CNY 0

Fudan-Zhangjiang to Release FY2025 Semi-Annual Earnings on August 12, 2025 (BJT)

Wang Haibo Sells 4.2707 Million Shares of Fudan Zhangjiang

Fudan Zhangjiang Announces DC Platform Development Progress

Yang Zongmeng's 减持 of Fudan Zhangjiang Shares Triggers 1% Threshold

Shanghai Fudan Zhangjiang Signs Structured Deposit Agreement with China Merchants Bank

688505

600000

01349

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. has invested RMB210 million in a low-risk structured deposit with SPD Bank. The deposit offers a floating annualized return of 0.70% to 2.05% over 87 days, linked to the EUR/USD exchange rate. This transaction exceeds 5% but is below 25% of applicable percentage ratios, requiring disclosure but not shareholder approval. The investment aims to optimize short-term liquidity while maintaining principal security, reflecting the company's strategy to manage idle funds through conservative financial products.

Tip Ranks

SPD Bank

FUDANZHANGJIANG

Fudan Zhangjiang Invests RMB210 Million in Low-Risk SPD Bank Structured Deposit

01385

Shanghai Fudan announced its performance for the fiscal year 2025, with operating revenue of 3.982 billion RMB, an increase of 10.9% year-on-year. It recorded a net profit of 232 million RMB, a decline of 59.4%, with earnings per share of 0.28 RMB. The final dividend is 0.58 RMB per 10 shares

AASTOCKS

SHANGHAI FUDAN

"Performance" Shanghai Fudan's annual net profit is 232 million RMB, a decrease of 59.4%, with a dividend of 0.58 RMB per 10 shares

588130

159837

512290

159992

512010

516930

516500

510660

159849

Fudan-Zhangjiang announced its performance report for the year 2025, achieving revenue of 686 million RMB (same below), a year-on-year decrease of 3.3%. The net loss attributable to shareholders was 157 million RMB, compared to a net profit of 39.73 million RMB in the previous year, turning from profit to loss; the loss per share was 0.15 RMB

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

"Performance" Fudan-Zhangjiang reported a full-year loss of 157 million RMB, turning from profit to loss

159316

Fudan-Zhangjiang issued a profit warning, expecting a net loss of between 120 million and 180 million RMB for the fiscal year 2025, compared to a net profit of 39.73 million RMB in the previous year. The reason is that the group is actively promoting the progress of research and development projects, with R&D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has accordingly adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately 100 million RMB in profit contribution from the products

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

"Profit Warning" Fudan-Zhangjiang estimates a full-year loss of 120 million to 180 million RMB

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB110 million in low-risk structured deposits from China Merchants Bank. The 83-day term products offer an expected annual return of 1.00%–1.65% linked to gold. This investment is classified as a cautious-risk transaction under Hong Kong listing rules, requiring reporting but not shareholder approval. The company aims to enhance returns on surplus cash while maintaining its risk profile and capital structure. Fudan-Zhangjiang is a biopharmaceutical firm focused on research and development in the healthcare sector, with a market cap of HK$965 million.

Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. has invested RMB150 million in a low-risk structured deposit with Bank of China, utilizing idle funds from its A-share public offering. The 84-day deposit, linked to the AUD/USD rate, offers a floating annualized return of 0.35% to 1.6539%. This transaction is disclosable under Hong Kong listing rules, reflecting the company's conservative treasury management strategy.

Fudan-Zhangjiang Places RMB150 Million in Low-Risk Bank of China Structured Deposit